CryoCell International Inc (CCEL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at CryoCell International Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.40 $ — 21% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 1.3% failed
- More than 10% revenue growth is expected for the coming year no data
- Share count grows by less than 3% a year -1.7% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 15.3% failed
- Gross margin at 40% or higher and without meaningful erosion 76.6% passed
- Goodwill from acquisitions does not grow faster than revenue 3.2% passed
- Net debt below twice EBITDA 7.5 x EBITDA failed
- Operating cash flow covers the profits of the last three years 32 m passed
- Return on capital at 15% or higher, or up versus two years ago 11.5% passed
- Insiders hold at least 10% or are net buyers 42.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 150.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.22 | – | 8 | 1.90 | -23.20 | 2 | 2 |
| 2025: Q1 | 0.03 | -57.10 | 8 | 1.50 | 3.60 | 1 | 1 |
| 2025: Q2 | 0.04 | -45.70 | 8 | -1.40 | 4.50 | 1 | 1 |
| 2025: Q3 | 0.09 | -30.80 | 8 | -3.00 | 20.70 | 3 | 3 |
| 2025: Q4 | -0.47 | – | 8 | -2.30 | -59.80 | 1 | 1 |
| 2026: Q1 | 0.01 | -66.70 | 8 | -3.60 | 0.60 | 1 | 1 |
| 2026: Q2 | 0.07 | 75.00 | 8 | -1.30 | 7.70 | 2 | 2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Cryo-Cell International, Inc. befasst sich mit der Kryokonservierung von Nabelschnurblut und Nabelschnurgewebe in den USA.
| Employees | 72 |
|---|---|
| Headquarters | Oldsmar, FL |
| Website | cryo-cell.com |
| IPO Date | 21. Jan 1997 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David I. Portnoy | Chairman & Co-CEO | 1963 |
| Mark L. Portnoy | Co-CEO & Director | 1964 |
| Jill M. Taymans | CFO & VP of Finance | 1970 |
| Oleg Mikulinsky | Chief Information Officer | 1973 |
| Joanne Kurtzberg M.D. | Medical Director and Member of Medical & Scientific Advisory Board | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.